Core Viewpoint - The company has announced an adjustment to its share repurchase plan, increasing the maximum repurchase price from RMB 35.00 per share to RMB 48.00 per share to ensure the smooth implementation of the plan [7][11][17]. Group 1: Share Repurchase Plan Overview - The company approved a share repurchase plan on June 26, 2025, allowing for the repurchase of its A-shares using self-owned funds and/or special loans, with a total repurchase amount between RMB 25 million and RMB 50 million [1][9]. - The repurchase period is set for 12 months from the date of board approval [1][9]. - As of July 31, 2025, the company has not yet implemented the share repurchase [2][10]. Group 2: Adjustment of Repurchase Price - The maximum repurchase price has been adjusted to RMB 48.00 per share due to the company's stock price exceeding the previous limit, which limited the implementation window [11][15]. - The adjustment is based on the company's confidence in its future development and aims to protect shareholder interests [11][16]. - The total repurchase amount remains unchanged, and the repurchase plan's other details are not affected by this adjustment [16][17]. Group 3: Company’s Business and Market Position - The company focuses on oncology and age-related diseases, with 16 core products in various stages of development, including 12 innovative drugs and 4 biosimilars [12]. - The company has several innovative drugs in critical clinical research stages, with notable achievements such as receiving multiple designations from the FDA for its drug 9MW2821 [12]. - The company has established international partnerships and is expanding its market presence, particularly in emerging markets along the Belt and Road Initiative [13].

Core Viewpoint - Maiwei Biopharma is advancing multiple key pipeline products in critical registration clinical research stages, with its core pipeline 9MW2821 being the first of its kind globally to enter Phase III for cervical cancer [2][3] Group 1: Pipeline and Clinical Trials - The company has 16 pipeline products in various stages, including 12 innovative drugs and 4 biosimilars, focusing on oncology and age-related diseases [2] - 9MW2821 is involved in multiple indications, including urothelial carcinoma (UC), cervical cancer (CC), triple-negative breast cancer (TNBC), and esophageal cancer (EC), with over 800 patients enrolled in clinical trials [3] - Three Phase III clinical trials are ongoing for 9MW2821, making it the first domestic product for UC and the second globally [3] Group 2: ADC Development Platform - Maiwei Biopharma is enhancing its proprietary ADC drug development platform to improve the efficacy and safety of ADC molecules [3] - The company’s ADC platform utilizes site-specific conjugation technology, resulting in higher uniformity and reduced batch-to-batch variability compared to traditional methods [3] Group 3: Commercial Performance - In 2024, the company achieved revenue of 200 million yuan, a year-on-year increase of 56.28%, with sales of its drug for bone diseases and tumors reaching 139 million yuan, a 230% increase [5] - The company has three marketed products and is expecting to launch another innovative drug in December 2023, with potential approval in 2025 [5] Group 4: Strategic Collaborations - Maiwei Biopharma signed a contract for a bone health innovation drug project with the Chongqing High-tech Industrial Development Zone, aiming to promote its products in local medical institutions [5] - The project is expected to cover over 1 million elderly individuals annually through new service models [5]

Core Viewpoint - The company, Maiwei Biotech, is actively advancing its innovative drug pipeline and has announced a capital increase for its wholly-owned subsidiary, Jiangsu Taikang Biopharmaceutical Co., Ltd, to enhance its operational capabilities and financial strength [15][18][20]. Financial Data - The company reported that its first-quarter financial statements are not audited [3]. - The company has a total of 16 core products in various stages of development, including 12 innovative drugs and 4 biosimilars, focusing on oncology and age-related diseases [5]. Drug Development Progress - The innovative drug 9MW2821 has been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) and is undergoing clinical trials for multiple cancer types, with over 800 patients enrolled [5][6]. - The drug 9MW1911, targeting chronic obstructive pulmonary disease (COPD), has completed its Phase Ib/IIa clinical trial with 80 patients and is preparing for a larger Phase II trial [6]. - The drug 9MW3011, aimed at treating polycythemia vera (PV), has initiated its first patient enrollment in a Phase Ib clinical study and is set to begin a Phase II study in the U.S. [7]. - The company is also developing 1MW5011 for osteoarthritis, which is currently in Phase II clinical trials [8]. Market Potential - The global market for COPD is projected to reach $60 billion by 2032, with significant growth expected in China [6]. - The company’s innovative drugs are positioned to address unmet medical needs in various therapeutic areas, including oncology and respiratory diseases, indicating a strong market potential [5][6][7]. Capital Increase - The company plans to increase the capital of Jiangsu Taikang Biopharmaceutical by 400 million yuan, raising its registered capital from 480 million yuan to 880 million yuan [16][18]. - This capital increase has been approved by the company's board and does not require shareholder approval, ensuring a streamlined process for enhancing the subsidiary's financial strength [17][20]. Academic and Strategic Collaborations - The company is actively participating in academic conferences and has published research on its drug candidates, showcasing its commitment to innovation and collaboration in the biopharmaceutical field [10]. - Strategic partnerships with AI technology firms are being pursued to enhance drug development efficiency and address unmet clinical needs [10].